Mirum’s maralixibat oral solution secures approval from Health Canada
26 Jul 2023
Drug ApprovalClinical Result
Preview
Source: Pharmaceutical Technology
LIVMARLI has been now authorised in Canada to treat cholestatic pruritus in patients with Alagille syndromeAlagille syndrome. Credit: Shidlovski /Shutterstock.com.
Mirum Pharmaceuticals has received approval from Health Canada for LIVMARLI (maralixibat) to treat cholestatic pruritus in patients with Alagille syndromeAlagille syndrome (ALGS), a rare genetic disorder caused due to reduced or malformed bile ducts.
The abnormalities in bile ducts lead to cholestasis, a condition where bile acids get accumulated in the bile ducts, thereby causing inflammation and improper functioning of the liver and then leading to progressive liver disease.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Elenestinib in Systemic Mastocytosis GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ranibizumab Biosimilar in Macular Edema GlobalData
View allCompanies IntelligenceMirum Pharmaceuticals IncHealth CanadaMirum IncIconicView all
This approval is supported by data from the ICONIC study, which includes six years of data across the LIVMARLI clinical programme.
The data from the study indicated statistically important and clinically relevant reductions in pruritus as against placebo, as well as a significant reduction of serum bile acids, both of which were maintained during the treatment for several years.
LIVMARLI, which is to be administered orally and once daily, is an ileal bile acid transporter inhibitorileal bile acid transporter inhibitor and is claimed to be the only approved drug by the US Food and Drug Administration (FDA) for treating cholestatic pruritus in ALGS patients aged three months and older.
Mirum Pharmaceuticals president and CEO Chris Peetz said: “This approval in Canada furthers our commitment to ensuring patients globally have a meaningful and effective treatment option for the unrelenting burden of cholestatic pruritus impacting patients and their families living with ALGS.
“We are grateful to the patients, families, clinicians and ALGS community who made this approval possible.”
The European Commission has also approved LIVMARLI for use in patients aged two months and above for the same indication.
Mirum has also submitted a supplemental new drug application (SNDA) to the FDA and European Medical Agency (EMA) for the use of LIVMARLI in treating cholestatic pruritus associated with progressive familial intrahepatic cholestasis (PFIC).
The SNDA to the FDA is intended for treating patients aged three months and older, while the submission to the EMA is for treating patients two months and older.
Both these submissions are currently under review by their respective authorities.
Furthermore, LIVMARLI is being assessed in late-stage clinical studies in treating other rare cholestatic liver diseases, including biliary atresia.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.